LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  by Kaufman, Jacob M. et al.
794 Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014
Introduction: Inactivation of serine/threonine kinase 11 (STK11 or 
LKB1) is common in lung cancer, and understanding the pathways 
and phenotypes altered as a consequence will aid the development 
of targeted therapeutic strategies. Gene and protein expressions in a 
murine model of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homo-
log (Kras)-mutant lung cancer have been studied to gain insight into 
the biology of these tumors. However, the molecular consequences of 
LKB1 loss in human lung cancer have not been fully characterized.
Methods: We studied gene expression profiles associated with LKB1 loss 
in resected lung adenocarcinomas, non–small-cell lung cancer cell lines, 
and murine tumors. The biological significance of dysregulated genes 
was interpreted using gene set enrichment and transcription factor analy-
ses and also by integration with somatic mutations and proteomic data.
Results: Loss of LKB1 is associated with consistent gene expres-
sion changes in resected human lung cancers and cell lines that differ 
substantially from the mouse model. Our analysis implicates novel 
biological features associated with LKB1 loss, including altered mito-
chondrial metabolism, activation of the nuclear respiratory factor 2 
(NRF2) transcription factor by kelch-like ECH-associated protein 
1 (KEAP1) mutations, and attenuation of the phosphatidylinosi-
tiol 3-kinase and v-akt murine thymoma viral oncogene homolog 
(PI3K/AKT) pathway. Furthermore, we derived a 16-gene classifier 
that accurately predicts LKB1 mutations and loss by nonmutational 
mechanisms. In vitro, transduction of LKB1 into LKB1-mutant cell 
lines results in attenuation of this signature.
Conclusion: Loss of LKB1 defines a subset of lung adenocarcinomas 
associated with characteristic molecular phenotypes and distinctive 
gene expression features. Studying these effects may improve our 
understanding of the biology of these tumors and lead to the identifi-
cation of targeted treatment strategies.
Key Words: Genomics, LKB1, NRF2, PI3K/AKT.
(J Thorac Oncol. 2014;9: 794–804)
Although genes activated by oncogenic mutations may be directly targetable with significant clinical benefit, strate-
gies to target tumor suppressor loss depend on the identification 
and exploitation of differences in pathway activation or cellu-
lar phenotypes that occur as a consequence of these lesions. 
One such tumor suppressor is LKB1, a  serine-threonine kinase 
tumor suppressor that is lost in approximately 30% of lung 
adenocarcinomas.1,2 It is a key regulator of cellular metabolism 
through its control of the adenosine monophosphate–activated 
protein kinase (AMPK); loss of this metabolic checkpoint 
in tumors results in activation of the mammalian target of 
rapamycin (mTOR) pathway and susceptibility to metabolic 
stress.3–5 LKB1 also affects development, cell polarity and 
motility, chromatin and transcriptional regulation, and cell 
growth by phosphorylating additional  AMPK-family mem-
bers and other mediators.6,7 Understanding these complex 
interactions may help identify targeted strategies for treating 
LKB1-deficient tumors and determine feedback and resistance 
mechanisms that may differ between LKB1-wild-type and 
LKB1-mutant tumors.
To study these processes, genetically engineered murine 
models of Lkb1/Kras-mutant lung cancer have been devel-
oped. The resulting tumors are aggressive, metastasize readily, 
and exhibit diverse histological differentiation similar to that 
observed in human non–small-cell lung cancer (NSCLC).1,8 
This model implicates up-regulation of transforming growth 
factor-beta and v-src avian sarcoma (Schmidt-Ruppin A-2) 
viral oncogene homolog (SRC) pathways in the biology of 
these tumors and particularly in the progression to metastasis.8 
In vivo testing of treatment regimens demonstrates that these 
murine tumors exhibit sensitivity to metabolic stress induced 
by phenformin5 but are resistant to mitogen activated protein 
kinase pathway inhibition.9 Although mouse models are use-
ful tools for studying tumor biology, the validity of the Lkb1/
Kras lung tumor model in predicting human disease pheno-
types has not been evaluated.
In this study, we describe gene expression changes and 
other molecular phenotypes associated with the loss of the 
LKB1 tumor suppressor in human tumors and cell lines. Our 
approach is outlined in Figure 1. Loss of LKB1 often occurs 
by somatic mutation,7 but other mechanisms of inactivation 
also contribute, such as methylation, homozygous deletion, 
or intragenic deletions of one or more exons.10–12 Inactivation 
of this tumor suppressor in lung cancer is thought to require 
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complete or nearly complete loss of LKB1 function, regard-
less of the underlying mechanism. Thus, we will refer to these 
processes collectively as instances of “LKB1 loss,” or as an 
“LKB1-deficient” tumor, with the presumption—supported by 
our later findings—that these alterations yield similar tumor 
phenotypes.
Our analysis demonstrates that LKB1 loss is associated 
with a consistent pattern of gene expression across resected 
human NSCLC tumors and cell lines. A predictive signature 
derived from this pattern accurately classifies mutational 
and nonmutational loss of LKB1 in multiple validation sets. 
However, this pattern is not recapitulated in the murine 
model. Gene expression patterns and associations with other 
molecular features implicate activation of the forkhead box 
A2 (FOXA2), forkhead box O3 (FOXO3), cyclic-AMP 
responsive element binding protein (CREB), and NRF2 
transcription factors and decreased PI3K/AKT signaling 
in tumors with LKB1 loss. By defining these dysregulated 
processes, this work will guide future research efforts aimed 
at understanding the complex effects of these pathways in 
determining phenotypic and clinical consequences in tumors 
that have lost LKB1.
MATERIALS AND METHODS
Clinical and Molecular Data sets
Preprocessed and normalized data for RNAseq gene 
expression, microRNA expression, copy number altera-
tions, protein expression, somatic mutations, and clinical 
data for lung adenocarcinomas characterized by The Cancer 
Genome Atlas (TCGA) were obtained from the TCGA Web 
site. Processed gene expression data, somatic mutations, and 
clinical information for other publicly available data sets 
were downloaded from Gene Expression Ominbus (GEO) 
and ArrayExpress or from individual Web sites, as listed in 
Supplementary Table S1 (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A585). In cases where data were 
presented as linear expression values, log2 transformed values 
were used. The status of LKB1 loss in NSCLC cell lines was 
taken from various previous studies given in Supplementary 
Data File 1 (Supplementary Digital Content 2, http://links.
lww.com/JTO/A586).
Gene expression analysis of A549 and H2122 cell 
lines transduced with pBABE, LKB1, or LKB1-K78I was 
performed using HT Human Gene 1.1 ST PM16 array plate 
Interpretation of potential 
biological significance of 
LKB1-associated genes 
(e.g. by GSEA):
FOXO3
FOXA2
CREB
NRF2
mTOR
Development and validation of 16-gene 
signature for predicting LKB1 loss
Identification of molecular and clinical 
features of LKB1 loss:
Somatic mutations
Copy number alterations
Protein expression
microRNA
Characterization
of LKB1-
associated genes 
across 15 studies
Resected lung
adenocarcinomas
NSCLC
Cell lines
LKB1/KRAS
Mouse model
LKB1 add-back
Isogenic cell line 
model
FIGURE 1.  Schema showing analysis and experi-
ments presented in this work. NSCLC, non– small-
cell lung cancer; LKB1, liver kinase B1; KRAS, 
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homo-
log; LUAD, lung adenocarcinoma; GSEA, gene set 
enrichment analysis; FOXO3, forkhead box O3; 
FOXA2, forkhead box A2; CREB, cAMP responsive 
element binding protein; NRF2, nuclear respiratory 
factor 2; mTOR, mammalian target of rapamycin.
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using a GeneTitan instrument (Affymetrix; Santa Clara, CA). 
They were then scanned on the Affymetrix Gene Titan AGCC 
v. 3.2.3 and then analyzed on Affymetrix Expression Console 
v. 1.1 using an robust multi-array average (RMA) normaliza-
tion algorithm producing log2 results. These data are available 
from GEO data repository (GSE51266).
Statistical Analyses
Two-sided student's T-tests were used to compare statis-
tical differences in continuous variable distributions between 
groups of samples: for instance, gene expression differences 
between LKB1 wild-type and mutant tumors. For comparison 
of discrete variables such as the presence of somatic muta-
tions, statistical significance was determined using Fisher’s 
exact test. Statistical associations between continuous vari-
ables such as LKB1 mRNA expression were determined using 
linear regression. Visualization of gene expression patterns by 
hierarchical clustering was performed with Cluster 3.0 and 
TreeView software packages. For the four expression clusters 
defined by hierarchical clustering, cluster “scores” were cal-
culated for a given set of samples by averaging the standard-
ized values of the respective genes. The score for the 16-gene 
LKB1-loss classifier, equivalent to the FOX/CREB cluster, 
was used for prediction of LKB1 status in clinical and cell line 
samples. LKB1-loss scores for NSCLC cell lines are given in 
Supplementary Data File 1 (Supplementary Digital Content 2, 
http://links.lww.com/JTO/A586).
Gene expression associations for the four transcrip-
tional clusters were calculated using multivariable general lin-
ear regression models carried out with the ‘Limma’ package 
in R bioconductor software, (R foundation for statistical com-
puting, Vienna, Austria). Transcription factor analysis was 
performed using the Broad Institute’s Molecular Signature 
Database,13,14 and initial perturbation analysis was performed 
using the Connectivity Map.15 Detailed information on data 
sources and statistical comparisons made for various analy-
ses is given in Supplementary Table S1 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A585) and in 
Supplementary Methods (Supplementary Digital Content 3, 
http://links.lww.com/JTO/A587).
Cell Culture and Gene Transduction
A549 and H2122 cell lines were generously shared 
with us by John Minna and Luc Girard (University of Texas, 
Southwestern, Dallas, TX). Cell line identity was authenticated 
by DNA fingerprinting, and cell lines were tested to ensure that 
they were mycoplasma negative. Cells were cultured in Roswell 
Park Memorial Institute 1640 (RPMI1640) cell growth media, 
(GIBCO, Carlsbad, CA) containing 5% fetal bovine serum, 
without antibiotics. Empty pBABE viral plasmids, pBABE-
LKB1 and pBABE-LKB1-K78I, were obtained from Addgene 
(Cambridge, MA). Phoenix cells were transfected with viral plas-
mids and retroviral particles were harvested from media superna-
tant 48 hours after transfection. Viruses were added to target cells 
with polybrene, and selection with 1 μg/ml puromycin was begun 
48 to 72 hours after infection. Cells were selected under puromy-
cin for 1 to 2 weeks before performing subsequent experiments, 
with experiments being completed within 2 months.
Immunoblots
Cell lysates were harvested while cells were in exponential 
growth phase in radioimmunoprecipitation assay (RIPA) lysis 
buffer containing phosphatase and protease inhibitors. Lysates 
were homogenized and run on precast sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gels (BioRad, Hercules, 
CA). Phospho-ACC (s79), ACC, RS6, and LKB1 antibodies 
were obtained from Cell Signaling Technology, Danvers, MA.
CRE-Luciferase Reporter
We designed a dual-luciferase reporter driven by a ×3 
cyclic-AMP responsive element (CRE) consensus-binding 
sequence in the promoter region in addition to a TATA box, 
which was inserted into a lentiviral construct upstream of 
luciferase. Luciferase activity from this reporter was com-
pared with a control reporter that was identical but with 
mutated CRE sites. Cells were stably transduced to express 
CRE-wild-type or CRE-mutant reporters and ratios between 
the two were compared after subsequent perturbations.
More detailed descriptions of statistical and analyti-
cal procedures are available with Supplementary Methods 
online (Supplementary Digital Content 3, http://links.lww.
com/JTO/A587).
RESULTS
LKB1 Loss Results in Consistent Gene 
Expression Changes in Human Tumors
The effects of signaling pathways are mediated in part 
by activation of transcription factors affecting the expression 
of downstream genes. Inferences drawn from the analysis 
of the dysregulated genes may disclose novel links between 
pathways and phenotypes that would otherwise be difficult 
to predict. We determined gene expression changes associ-
ated with LKB1 loss in lung adenocarcinomas characterized 
by the TCGA (Cancer Genome Atlas Research Network). 
Comprehensive molecular characterization of lung adeno-
carcinoma. Nature. 2014), as well as five additional studies 
of resected lung adenocarcinomas16–20 two large collections 
of NSCLC cell lines21,22 and data from two studies using 
the Lkb1/Kras murine model1,8 (Supplementary Table S1, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A585). Genes with differential expression between LKB1-
mutant and LKB1-wild-type samples were ranked by statisti-
cal significance for each data set (Supplementary Data File 
2, Supplementary Digital Content 4, http://links.lww.com/
JTO/A588). These LKB1-associated gene lists were then 
compared pairwise across all data sets, and statistical signifi-
cance of overlapping genes was used to determine similarity 
(Fig. 2A; Supplementary Figure S1 [Supplementary Digital 
Content 5, http://links.lww.com/JTO/A589]; Supplementary 
Table S2 [Supplementary Digital Content 1, http://links.lww.
com/JTO/A585]). A consistent pattern of gene expression is 
associated with LKB1 loss across human data sets (median p 
value = 3.8e-18 for 55 pairwise comparisons). Murine Lkb1 
loss also resulted in a consistent gene expression signature 
across the two studies, but without significant overlap with 
the human studies, suggesting important differences in tumor 
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biology (Fig. 2A; Supplementary Figure S1 [Supplementary 
Digital Content 5, http://links.lww.com/JTO/A589]).
Having established that LKB1 loss results in consistent 
patterns of gene expression in human lung adenocarcinomas, we 
used two clinical data sets—one analysis of lung adenocarcino-
mas from University of Michigan (n = 178) and one character-
ized by Washington University (n = 41)—as training cohorts to 
identify 129 genes associated with LKB1 loss (Supplementary 
Data File 2, Supplementary Digital Content 4, http://links.lww.
com/JTO/A588). Expression of these genes was visualized 
using hierarchical clustering, as shown for the Michigan train-
ing set and the TCGA validation set (Fig. 2B, C). Comparison 
of the correlation patterns in these two data sets allows identi-
fication of four consistently expressed transcriptional clusters 
(Fig. 2B, C; Supplementary Figure S2 [Supplementary Digital 
Content 5, http://links.lww.com/JTO/A589]). However, the cor-
relation patterns of the down-regulated genes were not as repro-
ducible across multiple data sets as the up-regulated genes, 
so we will focus our attention on the three clusters that show 
increased expression in LKB1-deficient tumors.
Computational Approaches Identify 
Putative Drivers of Expression Clusters 
Associated with LKB1 Loss
The pattern of gene expression associated with LKB1 
loss may be reflective of biological processes altered in these 
tumors. We sought to identify transcription factors putatively 
associated with these genes using a bioinformatics approach. 
For each of the four clusters identified, ranked lists of gene 
expression association were determined using a multivariable 
linear model. The top 200 genes associated with each cluster 
were then used to generate hypotheses regarding the pathways 
or phenotypes that drive the expression of these clusters by 
mining public data sources, including predicted promoter 
transcription factor–binding sites,13 drug-induced perturba-
tions characterized by the connectivity map project,15 and the 
diverse collections of predetermined genesets included in the 
molecular signature database.13,14
Two of the up-regulated clusters showed associations 
with tumor metabolic phenotypes. The “mTOR/mitochon-
dria” cluster was associated with high expression of oxida-
tive phosphorylation and mitochondria-associated genes and 
genes involved in protein translation (Supplementary Table 
S3, Supplementary Digital Content 1, http://links.lww.com/
JTO/A585). The “NRF2” cluster contains oxidative stress 
response genes driven by the NRF2 transcription factor 
(Supplementary Table S4, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A585). As LKB1 functions in con-
junction with AMPK as a metabolic regulator,6,7,23 these phe-
notypes may either represent direct metabolic consequences 
of LKB1 loss or adaptive responses to compensate for loss of 
protective mechanisms.
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FIGURE 2. LKB1 loss produces a characteristic pat-
tern of gene expression. A, The statistical significance 
of gene overlap is shown for pairwise comparisons of 
the top 200 genes overexpressed in tumors with LKB1 
loss in 15 studies of lung adenocarcinomas. Asterisks 
indicate comparisons between cell lines expressing 
vector control and those expressing wild-type LKB1. 
The two cell line studies, CCLE and Sanger, contain 
many overlapping cell lines; thus, their results were 
not independent but demonstrate consistency of 
these patterns across the two data sets. p values from 
a hypergeometric test are color coded according 
to the legend. B and C, Unsupervised hierarchical 
clustering of resected lung adenocarcinomas from the 
(B), Michigan cohort from the Director’s Challenge 
study (n = 178) or (C) from the TCGA (n = 446) using 
a 129 gene signature of LKB1 loss. Tumors are shown 
on the horizontal axis, with loss of LKB1 highlighted 
in red; genes are represented on the vertical axis. 
Four clusters of genes, demarcated by yellow lines, 
are observed in each of these data sets. TCGA, The 
Cancer Genome Atlas; LUAD, lung adenocarcinoma; 
MSKCC, Memorial Sloan Kettering Cancer Center; 
UNC, University of North Carolina; CCLE, Cancer Cell 
Line Encyclopedia; NS, not significant; LKB1, liver 
kinase B1; mTOR, mammalian target of rapamycin; 
NRF2, nuclear respiratory factor 2; FOX, forkhead 
box; CREB, cyclic-AMP responsive element binding 
protein.
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Analysis of a third cluster of up-regulated genes 
implicated CREB, FOXO, and FOXA2 transcription factors 
(Supplementary Table S5, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A585). Of the four gene clusters 
identified, the FOX/CREB cluster had the strongest association 
with LKB1 loss in the training cohort. Analysis of perturbed 
genes from the connectivity map also revealed induction of 
this cluster by colforsin, an adenylate cyclase stimulator that 
activates CREB, and by the typical antipsychotics thiorida-
zine, prochlorperazine, and trifluoperazine, which have been 
identified as stimulators of FOXO transcription factors.24 We 
then searched the GEO and Array Express data repositories 
and found corroborating evidence for CREB and FOXO3 acti-
vation within this cluster. Furthermore, analysis of chromatin 
precipitation data25 showed significantly increased levels of 
FOXA2 promoter occupancy among these genes in A549 and 
HEPG2 cells. Thus, this cluster may represent the effects of 
a specific set of transcription factors that are dysregulated 
downstream of LKB1.
Wild-Type LKB1 Attenuates the 
LKB1-Associated Signature
To test whether LKB1 could exert direct effects on gene 
expression, we used an isogenic cell line model system in 
which LKB1 was stably expressed in LKB1-mutant NSCLC 
cell lines (A549 and H2122). Mutated LKB1-K78I and empty 
pBABE retrovirus were used as controls. LKB1 expression 
was confirmed by Western blot, and kinase activity was shown 
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FIGURE 3.  Restoring wild-type LKB1 
attenuates the expression of the LKB1-
deficient gene signature and the CREB 
transcription factor. A, Immunoblots 
of whole-cell lysates from A549 and 
H2122 stably expressing empty pBABE 
vector, LKB1 or K78I LKB1. Ribosomal 
protein S6 is used as a loading control. 
B and C, Changes in gene expres-
sion of A549 (B) or H2122 (C) cell 
lines after  re-expressing wild-type or 
mutant LKB1 were compared with the 
gene lists for each of the four LKB1-
associated clusters using a hyper-
geometric test. Log10 p values are 
indicated on the y axis, with positive 
values indicating induction of expres-
sion and negative values indicating 
repression. D, Activity of CRE-luciferase 
is shown for A549 and H2122 cell lines 
after stable expression of LKB1 or K78I 
LKB1. Reporter activations were deter-
mined relative to a control luciferase 
with mutated CRE sites and are shown 
relative to the pBABE control. p values 
show the significance of unpaired 
student’s t tests. LKB1, liver kinase B1; 
CREB, cyclic-AMP responsive element 
binding protein; pBABE, pBABE retrovi-
rus; FOX, forkhead box protein; NRF2, 
nuclear respiratory factor 2.
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by demonstrating that wild-type LKB1 resulted in phosphory-
lation of acetyl-CoA-carboxylase, a downstream target of 
AMPK (Fig. 3A) in A549 and H2122 cells.
Global gene expression analysis showed that genes 
directly altered by LKB1 expression in A549 and H2122 showed 
significant overlap with the differentially expressed genes 
from our analysis of clinical and cell line data sets (Fig. 2A; 
Supplementary Figure 1 [Supplementary Digital Content 5, 
http://links.lww.com/JTO/A589]). By comparing the overlap 
of LKB1-perturbed genes to each of the top 200 genes associ-
ated with the four gene clusters from our previous analysis, 
we show that genes affected directly by LKB1 expression 
showed the strongest association with the FOX/CREB gene 
cluster (hypergeometric test p values = 1.3e-30, 3.6e-45 for 
A549 and H2122; Fig. 3B, C), whereas mTOR/mitochondria 
and NRF2-associated clusters were relatively unaffected. 
Many of the 16 individual genes that originally identified the 
FOX/CREB cluster were down-regulated by twofold or more 
in response to LKB1 expression (Supplementary Figure S3, 
Supplementary Digital Content 5, http://links.lww.com/JTO/
A589). Because this gene cluster was linked in part to CREB 
activity, we also tested CREB transcriptional activity in A549 
and H2122 cell lines using a luciferase reporter driven by 
the CREB-consensus sequence, which showed a reduction in 
reporter activity of 30% to 40% (Fig. 3D; p < 0.05 for each 
cell line). This is consistent with previous studies showing 
CREB to be directly attenuated downstream of LKB1 due 
to effects on the CREB regulated transcription coactivator 
(CRTC) family of transcriptional coactivators.26–28
A 16-Gene Classifier Accurately Predicts 
LKB1 Mutations in Lung Adenocarcinoma
The FOX/CREB cluster showed a strong association 
with LKB1 mutations in the training cohort and its expres-
sion was also directly attenuated by the restoration of wild-
type LKB1 in vitro. Thus, we tested the ability of a 16-gene 
classifier (AVPI1, BAG1, CPS1, DUSP4, FGA, GLCE, HAL, 
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FIGURE 4.  A 16-gene signature of LKB1 loss accurately predicts LKB1 mutations, loss of LKB1 expression, and loss of function. 
A, The population distribution is shown for numeric LKB1-loss scores calculated for 446 lung adenocarcinomas from the TCGA. 
Parameters are shown for calculations of best fit to a bimodal distribution; these parameters, and the two associated normal 
distributions, are shown. B, On the basis of the parameters for the two normal distributions determined for this population, 
the probability of a given score representing the high-expression LKB1 loss curve is shown. C, Sensitivity and specificity of the 
LKB1 classifier for prediction of LKB1 mutations across independent testing sets; p value represents the result of the Fisher’s 
exact test. D, Expression of LKB1 mRNA is shown for TCGA lung adenocarcinomas grouped by LKB1 mutation and LKB1-loss 
signature classification status. E, Expression of phospho-AMPK T172 is shown for the subset of TCGA lung adenocarcinomas 
with RPPA data, which were grouped by LKB1 mutation and LKB1-loss signature classification status. D and E, Each dot repre-
sents one tumor, with red bars indicating the median expression. p values represent results from the student’s t test comparing 
indicated groups. RPPA, reverse phase protein array; TCGA, The Cancer Genome Atlas; AMPK, adenosine monophosphate–
activated protein kinase; LKB1, liver kinase B1; WT, wild-type; NS, not significant.
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IRS2, MUC5AC, PDE4D, PTP4A1, RFK, SIK1, TACC2, 
TESC, and TFF1) representing this gene cluster to discrimi-
nate LKB1-deficient tumors from those with functional 
LKB1. Standardized gene values were averaged for these 16 
genes to give a single numeric score for each tumor in a 
data set. These scores exhibited a bimodal distribution, from 
which we could estimate a class probability and calculate 
an inherent misclassification rate of 6.5% because of the 
region of overlap in the two underlying distributions (Fig. 
4A, B). A cutoff value of 0.2 was selected from the training 
analysis and was used to classify tumors as LKB1 wild-type 
or LKB1 loss.
We then tested the ability of the signature to predict 
LKB1 mutations in independent validation sets: a pooled 
analysis of previously published resected lung adenocarcino-
mas, lung adenocarcinomas characterized by TCGA (Cancer 
Genome Atlas Research Network. Comprehensive molecu-
lar characterization of lung adenocarcinoma. Nature. 2014), 
and NSCLC cell lines. No samples from these validation sets 
were used at any point in the derivation of our signature from 
the stated training sets. LKB1 mutations were accurately pre-
dicted in each of the lung cancer validation cohorts with a 
combined sensitivity of 93%; 22 of 26 somatic LKB1 muta-
tions in the pooled cohort, 65 of 67 in the TCGA cohort, and 
36 of 39 in NSCLC cell lines (sensitivity 85%, 97%, and 
92%; p =  2.8e-9, 2.5e-33, and 1.2e-16; shown in Fig. 4C and 
Supplementary Figure S4, Supplementary Digital Content 5, 
http://links.lww.com/JTO/A589).
We further tested our LKB1-loss signature alongside 
previously reported studies by using gene set enrichment anal-
ysis to compare the various gene lists to the genes differen-
tially expressed by LKB1 mutant tumors in the largest dataset 
- the TCGA cohort - and those directly perturbed by LKB1 in 
our in vitro study. The previous work available for compari-
son include three studies that examined the in vitro effects of 
LKB1 add-back in A549,1,29 H2126,1 and HeLa30 cells, a previ-
ous report of gene expression changes associated with LKB1 
mutations,31 and expression profiles associated with the “mag-
noid” subtype of lung adenocarcinomas,18 which has been 
shown to have an increased prevalence of LKB1 mutations 
(Supplementary Table S6, Supplementary Digital Content 
1, http://links.lww.com/JTO/A585). This analysis shows that 
LKB1 has consistent effects on gene expression in cell lines 
seen in our analysis and previous work, including similar 
changes in the nonlung HeLa cell line. The genes identified 
by Fernandez et al. do not seem to be reproducibly associated 
with LKB1 loss in our analysis. On the other hand, genes asso-
ciated with the “magnoid” subtype show significant overlap 
with LKB1-associated genes, but to a much lesser extent than 
is observed for the LKB1-loss signature.
LKB1 Wild-Type Lung Adenocarcinomas 
That Express the LKB1-Loss Signature 
Show Evidence of LKB1 Inactivation
Twenty-three percent of tumors without known LKB1 
mutations were classified as having LKB1 loss. However, 
some mutations may have been unrecognized, and there are 
multiple mechanisms by which tumor suppressors can be 
inactivated in addition to somatic mutation.10–12 Thus, we 
looked for additional evidence of LKB1 loss by examining 
LKB1 mRNA expression measured by RNAseq, and LKB1 
protein expression and phosphorylation of AMPK-T172 in the 
subset of tumors that were also characterized by reverse phase 
protein array. Among the 67 tumors with identified muta-
tions in LKB1, LKB1 mRNA expression and phospho-AMPK 
are strongly decreased (Fig. 4D, E; p = 4.7e-26 and 5.7e-11, 
respectively, by Student’s t test). Low pAMPK is consistent 
with the loss of LKB1 kinase activity, whereas decreased 
mRNA expression reflects the fact that of these 67 mutations, 
49 (73%) are nonsense, splice site, or frameshift alterations 
that are expected to lead to reduced mRNA expression by 
nonsense-mediated decay.32 LKB1 protein is also decreased 
among these 67 mutant tumors (p = 0.030); the moderate sta-
tistical significance associated with this observation compared 
with that associated with phosphorylated AMPK may reflect 
differences in antibody specificity.
When the same analysis is applied to the 74 LKB1 
 wild-type tumors that express the LKB1-loss gene signature, 
these tumors exhibit the same characteristics of LKB1 loss: 
these tumors have low LKB1 mRNA expression (p =  7.3e-28; 
Fig. 4D), low LKB1 protein expression (p = 0.011), and show 
loss of LKB1 kinase activity as demonstrated by attenu-
ated phosphorylation of AMPK-T172 (p = 1.7e-7; Fig. 4E). 
Moreover, when the 67 tumors with known LKB1 mutations 
are compared with the 74 LKB1-wild-type tumors that are 
predicted to have LKB1 loss, no significant differences are 
observed in LKB1 protein or mRNA expression or of AMPK 
phosphorylation (Fig. 4D, E). These tumors likely represent 
unrecognized cases of LKB1 loss that could occur by unde-
tected mutation, intragenic deletion, chromosomal loss, or by 
an epigenetic mechanism. This finding suggests that the classi-
fier may significantly surpass the observed specificity of 77% 
and shows that the LKB1-loss classifier is more sensitive than 
DNA sequencing for the detection of functional LKB1 loss.
Determination of Other Tumor 
Characteristics Associated with LKB1 Loss
Differentially expressed genes associated with LKB1 
loss can be studied directly to infer patterns of transcription 
factor activation that may reflect underlying differences in 
pathway activation. To better understand other phenotypes of 
LKB1 loss, we performed statistical comparisons to determine 
differences in clinical characteristics, copy number alterations, 
microRNA expression, protein expression, and mutation prev-
alence between LKB1-wild-type lung adenocarcinomas and 
those with LKB1 loss (Fig. 5, Supplementary Tables S7–S10, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A585). The 16-gene classifier was used to determine LKB1 
status of TCGA-characterized lung adenocarcinomas for the 
purpose of these comparisons.
To uncover novel associations between LKB1 loss and 
alterations in other pathways, we studied the prevalence of 
somatic mutations in the TCGA cohort of lung adenocarcino-
mas using a defined set of cancer genes (Catalog of Somatic 
Mutations in Cancer [COSMIC] Cancer Gene Census). Of the 
32 genes with at least a 5% mutation rate in this cohort, five 
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showed significant differences on the basis of LKB1 status. 
KRAS, KEAP1, and ATM were mutated more frequently in 
tumors that had lost LKB1, whereas EGFR and p53 mutations 
were less common (Fig. 5A). We were able to test associations 
with EGFR, KRAS, and p53 mutations independently using 
a pooled analysis of publicly available lung adenocarcinoma 
cohorts. Consistent with results from a prior study,33 this 
analysis confirmed fewer EGFR mutations (p = 1.9e-10) and 
increased prevalence of KRAS mutations (p = 0.00035) among 
tumors with LKB1 loss. No association with p53 loss was 
FIGURE 5.  Clinical and molecular features associated with LKB1 loss. A, Somatic mutations in key cancer genes occur at different 
frequencies among tumors with LKB1 loss. Fisher’s exact test was used to compare mutation count data from exome sequenc-
ing data among lung adenocarcinomas characterized by the TCGA and classified using the LKB1-loss signature as either LKB1 
wild-type (n = 267) or LKB1-loss (n = 136). Analysis was limited to genes with a mutation prevalence of at least 5% taken from a 
specified list of cancer-related genes (n = 32). Q-values represent correction of raw p values for this multiple hypothesis testing. B, 
Schema showing the role of the PI3K/AKT pathway in regulating mTOR activity. Analysis of differential protein or phosphorylation 
expression was performed with the Student’s t test, using RPPA data from lung adenocarcinomas characterized by the TCGA and 
classified using the LKB1-loss signature as either LKB1 wild-type or LKB1-loss. Selected proteins are shown using colors that cor-
respond to p values indicated in the legend, with blue indicating decreased expression in tumors with LKB1 loss. The complete list 
of differentially expressed proteins is given in Supplementary Table S9 (Supplementary Digital Content 1, http://links.lww.com/
JTO/A585). C, Resected lung adenocarcinomas characterized by TCGA (n = 372) were classified as LKB1-loss or LKB1 WT using the 
LKB1-classifier score. Kaplan–Meier curves were used to plot cumulative events for these two groups for overall survival, p value 
represent the results of the log-rank test; the number of evaluable tumors remaining are given at yearly intervals below the plot. 
RPPA, reverse phase protein array; TCGA, The Cancer Genome Atlas; CI, confidence interval; AMPK, adenosine monophosphate–
activated protein kinase; LKB1, liver kinase B1; KEAP1, kelch-like ECH-associated protein 1; EGFR, epidermal growth factor recep-
tor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ATM, ataxia telangectasia mutated; PI3K, phosphatidylinositiol 
3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; RAS, rat sarcoma (RAS) oncogene family; RAF, v-Raf oncogene family; 
MEK, MAPK/ERK kinase; ERK, extracellular regulated signal kinase; RHEB, Ras homolog enriched in brain; SOS, son of sevenless; 
GRB, growth factor receptor-bound protein ; SHC, Src homology 2 domain containing transforming protein; IRS, insulin receptor 
substrate; PDK1, 3-phosphoinositide-dependent protein kinase 1; TSC2, tuberous sclerosis complex 2; mTOR, mammalian target 
of rapamycin; WT, wild-type; AKT, v-akt murine thymoma viral oncogene homolog.
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observed in this pooled analysis, so this finding is of uncer-
tain significance. No data set was available to directly con-
firm associations with ATM and KEAP1 mutations. However, 
tumors with KEAP1 loss exhibited high levels of the “NRF2 
cluster” of gene expression, consistent with the direct role of 
KEAP1 in the degradation of the NRF2 transcription factor 
(Supplementary Figure S5, Supplementary Digital Content 
5, http://links.lww.com/JTO/A589). Thus, expression of this 
cluster seems to be indirectly linked to LKB1 loss, reflect-
ing instead the increased prevalence of KEAP1 loss in these 
tumors.
Associations between LKB1 loss and copy number 
alterations (Supplementary Table S7, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A585), microRNA 
expression (Supplementary Table S8, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A585), and protein 
expression (Supplementary Table S9, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A585) were also deter-
mined using TCGA data. Findings from analysis of reverse 
phase protein array proteomic data may be of particular 
interest, because these can potentially reflect states of path-
way activation that may be important for developing targeted 
interventions for LKB1-deficient tumors. Expression levels 
for 186 proteins and phosphorylated protein sites were com-
pared between these groups using the Student’s t test. Several 
components of the PI3-kinase pathway were down-regulated 
among tumors with LKB1 loss, suggesting that this pathway 
may be attenuated in these tumors. Differentially expressed 
proteins and phosphorylations are mapped onto a sche-
matic drawing representing key features of this pathway34–36  
(Fig. 5B). Both the p85 and p110 subunits of PI3K showed 
significant decrease in expression (p = 0.00061 and 0.00047, 
respectively), as well as decreased phosphorylation of PDK1 
at serine 241 (p = 0.00012), and decreased total Akt (p = 0.02) 
and phospho-S473 Akt (p = 0.018). Surprisingly, proteomic 
evidence did not suggest significant mTOR activation, show-
ing only modest increase in eIF4E expression and decrease 
in 4E-BP1 (p = 0.037 and 0.032, respectively), with no sig-
nificant differences in other components of mTOR signaling. 
A complete list of the significant associations seen in this 
analysis is given in Supplementary Table S9 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A585).
Finally, we show that LKB1 loss has no prognostic 
significance in lung adenocarcinoma (Fig. 5C). There is no 
association with tumor stage or survival in either the TCGA 
or Director’s Challenge cohorts (Supplementary Table S10, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A585). Smoking status was the only clinical characteristic 
associated with LKB1 loss, with tumors arising from never-
smokers exhibiting a significantly lower prevalence of LKB1 
loss. These findings are consistent with prior analysis of the 
clinical significance of LKB1 loss.33
DISCUSSION
Our work integrates detailed molecular characterizations 
from a number of sources, combining knowledge of muta-
tions and other genetic alterations with analysis of gene and 
protein expression in lung adenocarcinomas. This gives the 
most comprehensive analysis to date of the consequences of 
LKB1 loss in lung adenocarcinomas, and the novel biological 
insights that we have uncovered will guide future experimen-
tation and may suggest therapeutic strategies to target these 
tumors. In particular, we show that LKB1 loss in lung adeno-
carcinomas is associated with a characteristic pattern of gene 
expression changes, which can be used to accurately predict 
LKB1 loss and is also directly responsive to LKB1 activation 
in vitro. We integrate analysis of these gene expression pat-
terns with data on somatic mutations and protein expression 
to describe novel associations between LKB1 and other onco-
genic pathways, especially activation of the NRF2 pathway for 
reactive oxygen detoxification and dysregulation of the PI3K/
AKT/FOXO3 pathway, both of which have important effects 
on multiple cellular phenotypes and can affect response to a 
variety of anticancer treatments. The identification of previ-
ously unknown phenotypes associated with LKB1 loss has 
also been a major rationale for the development and study of 
the murine model of Lkb1/Kras-mutant lung cancer. However, 
our meta-analysis of LKB1-associated gene expression shows 
that LKB1 loss produces distinctly different effects in murine 
tumors than in human lung adenocarcinomas and cell lines. It 
is unclear whether the dissimilarity in gene expression reflects 
differences in clinically relevant phenotypes. Further experi-
mentation is warranted to explore these differences.
Our characterization of gene expression patterns allowed 
us to develop and validate a 16-gene LKB1-loss signature that 
sensitively detects 93% of LKB1 mutations in resected lung 
adenocarcinoma while also identifying tumors that have lost 
LKB1 by other mechanisms. Previous analysis of cell lines 
has shown that homozygous deletion and intragenic deletion 
are common mechanisms of LKB1 loss in addition to somatic 
mutation.10–12 Our work suggests that sequencing efforts 
to detect LKB1 mutations may fail to detect about half the 
instances of LKB1 loss. Thus, combination of direct sequenc-
ing with an expression-based classifier could enhance detec-
tion of LKB1 loss, for instance to assess the effect of LKB1 
loss on response to mTOR inhibitors or other novel targeted 
agents in clinical trials.
In addition to the potential use of our signature as a 
clinical classifier, our study of the dysregulated genes asso-
ciated with LKB1 loss has given insight into the biology of 
LKB1-deficient tumors. Other integrated molecular analy-
ses have been applied to lung cancer (Cancer Genome Atlas 
Research Network. Comprehensive molecular characteriza-
tion of lung adenocarcinoma. Nature. 2014)18,37,38 and have 
disclosed novel associations that would be difficult to appreci-
ate with more targeted approaches, including association of 
LKB1 mutations with gene expression–defined subtypes of 
lung adenocarcinoma. Rather than taking a global approach 
used in many of these studies, our work focused specifically 
on LKB1 loss as a single phenotype of interest. Our subse-
quent analysis confirmed a role of CREB activation that has 
previously been shown to have important oncogenic effects 
in LKB1-deficient tumors and results from a well-understood 
mechanism involving LKB1-mediated regulation of CRTC 
transcriptional coactivators.26–28 Moreover, we identify addi-
tional transcription factors FOXO3, FOXA2, and NRF2 that 
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are active in LKB1-deficient tumors and may influence various 
phenotypes within these tumors. Our in vitro experiments also 
showed that restoring LKB1 expression led to down-regulation 
of significant subsets of these genes, demonstrating that LKB1 
affects the activity of the corresponding transcription factors 
through direct downstream mechanisms.
Each of the factors we identify is known to influence key 
phenotypes in cancer. Further studies examining their effects 
and interactions in the context of LKB1 loss may be particu-
larly informative. For instance, NRF2 is a key activator of the 
oxidative stress response and also plays a role in metabolic 
reprogramming of cancer cells.39,40 LKB1-deficient tumors 
have been shown to be susceptible to oxidative stress, because 
they are unable to make the appropriate adaptive responses 
in metabolism and biosynthesis.5,41 NRF2 is frequently acti-
vated by somatic mutations in KEAP1 in NSCLC,42,43 and our 
analysis of the TCGA lung adenocarcinomas shows that the 
odds of a tumor having a KEAP1 mutation are increased more 
than sixfold among tumors with LKB1 loss. This high level 
of overlap may suggest that selective pressure exists for the 
activation of NRF2 as a secondary protective mechanism to 
compensate for LKB1 loss.
Down-regulation of the PI3K/AKT pathway is also evident 
among resected lung adenocarcinomas with LKB1 loss. The 
mechanism by which LKB1 loss decreases PI3K/AKT signaling 
is unclear, but several possibilities are worth mentioning. 
One possibility is that mTOR activation resulting from LKB1 
loss could result in feedback inhibition of PI3K/AKT signal-
ing,44 analogous to the effects seen in tumors exhibiting TSC2 
loss.45,46 Direct interaction of LKB1 and AKT has also been 
demonstrated,47 and LKB1 has been shown to facilitate AKT 
activation and exert antiapoptotic effects, including inhibitory 
phosphorylation of the proapoptotic FOXO3 transcription 
factor.47,48 Of note, activation of FOXO3 was also suggested 
by analysis of gene expression, showing that  down-regulation 
of the PI3K/AKT pathway may result in alterations in down-
stream pathway activation. This work guides future functional 
experiments to explore the interplay of LKB1 with these vari-
ous pathways and the resulting effects on clinically relevant 
phenotypes such as response to targeted inhibitors.
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